Citi has updated its model for GlobalFoundries, lifting the price target to $42 and extending its valuation horizon to 2027. The move follows the chipmaker's strategic acquisition of Synopsys' ARC Processor IP business, aimed at accelerating its physical AI roadmap.
SunPower has completed its inaugural installation of high-efficiency Monolith solar panels from REC Silicon in California's Santa Cruz, with local installer Cobalt Power Systems reporting immediate sell-out of initial inventory. The move comes amid surging demand from tech-savvy homeowners and follows SunPower's recent quarterly revenue growth.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
The fast-casual salad chain's stock fell sharply this week, pressured by a broader retreat in growth stocks and a reiterated sell call from Goldman Sachs, despite positive signals from the broader restaurant sector.
While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.
Global agribusiness leader Bunge Ltd. (BG) reached a fresh three-year high this week, buoyed by strong technical indicators and sustained momentum in the essential food supply chain sector, even as analyst price targets remain widely dispersed.
Shares of Cushman & Wakefield have surged 35.8% in six months, dramatically outpacing the broader market. While strong quarterly results fueled the climb, a deeper look at the firm's long-term financial health reveals potential headwinds that could give investors pause.
While ICF International's stock has kept pace with the broader market, analysts highlight concerns over declining backlog and slowing revenue growth, suggesting investors may find better opportunities elsewhere.
Standex International reported resilient Q1 2025 earnings with record gross margins above 40%, while announcing a transformative $462 million acquisition of Amran/Narayan Group, a leader in instrument transformers, aiming to double its exposure to fast-growing electrical infrastructure markets.
The Cleveland-based RIA platform has appointed three senior executives as its assets under management soar, positioning the firm for its ambitious target of $20 billion by 2027.
Campbell Soup Company will shutter its Hyannis, Massachusetts facility, the original home of Cape Cod Potato Chips, citing economic inefficiency. The closure, affecting 49 jobs, marks a strategic shift of production to larger plants as the snack giant consolidates its network.
Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.
While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.
As earnings season winds down, the construction and maintenance services sector showed resilience. Great Lakes Dredge & Dock posted solid results despite a revenue miss, while peers like Primoris soared. We analyze the key drivers and what's next for these industrial players.
The third-quarter earnings season reveals a sector at a crossroads. While government and technical consulting firms like Jacobs Solutions benefit from long-term structural trends, their latest financial results and market reactions paint a complex picture of resilience and recalibration.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A pivotal week for prediction markets saw Coinbase partner with Kalshi to offer event contracts nationwide, while the CFTC moved to establish clearer regulatory standards. Meanwhile, traders sharply increased bets on a potential U.S. government shutdown.
